NCT06976619View on ClinicalTrials.gov

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

March 31, 2029

Conditions
Type 1 DiabetesType 2 Diabetes
Interventions
DRUG

Liraglutide Pen Injector

Liraglutide 0.6mg

OTHER

Saline Injections

Saline in syringes to serve as placebo for single blind study

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER